Prof. Dr. Eduardo Candelario-Jalil received his Ph.D. in Pharmacology from the University of Havana, Cuba, in 2002. He did his first postdoctoral training in the Department of Psychiatry at the University of Freiburg, Germany. He studied the signal transduction pathways responsible for cyclooxygenase (COX)-2 upregulation in primary microglial cells and neurons during neuroinflammatory conditions and cerebral ischemia. He joined the University of New Mexico, USA, in 2006 to pursue his second postdoctoral training with Dr. Gary A. Rosenberg. He later became a Research Assistant Professor in the Department of Neurology at the University of New Mexico in 2008. In 2011, Dr. Candelario-Jalil moved to the University of Florida on a tenure-track faculty position in the Department of Neuroscience, McKnight Brain Institute. In July 2019, Dr. Candelario-Jalil was promoted to Associate Professor with tenure at the University of Florida, and in July 2024, he was promoted to full Professor. Dr. Candelario-Jalil’s research interests have been fostered by many years of work in neuropharmacology, biochemistry, and molecular biology. Dr. Candelario-Jalil directs an active research program with great translational potential, funded by two R01 grants from the NIH/NINDS. His research is focused on understanding neuroinflammatory mechanisms following ischemic stroke utilizing biochemical, cellular, genetic, pharmacological, and MRI multimodal approaches.